Use of somatostatin analogue for intestinal and pancreatic fistulas

H. Paran*, D. Neufeld, T. Epstein, J. Bendahan, U. Freund

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


The hormone somatostatin, a tetra-deca-peptide, was discovered in 1972. It inhibits the central nervous system and the endocrine and exocrine secretions of the gastrointestinal tract. The first clinical use of the hormone was to inhibit hormone-secreting tumors of the CNS. It has also been used to treat hormone-secreting tumors of the pancreas and GI tract. Treatment of small bowel and pancreatic fistulas has also been attempted. A new synthetic analogue of the hormone, SMS 210-995, (Sandostatin) has a long half-life and is highly effective after subcutaneous injection. It was used in the treatment of 3 patients with fistulas of the small bowel and pancreas. In all impressive reduction of fistula secretion was achieved within 24 hours. In 2 there was complete, spontaneous closure of the fistula: in 1 after 10 days and in the other after 15 days of treatment. In the 3rd, there was significant reduction of fistula output. There were no side-effects except for mild pain at the injection site in 1 patient. Previous reports and our own results indicate that this somatostatin analogue may be very useful in the nonsurgical treatment of GI tract fistulas.

Original languageEnglish
Pages (from-to)185-186
Number of pages2
Issue number4
StatePublished - 15 Feb 1991


Dive into the research topics of 'Use of somatostatin analogue for intestinal and pancreatic fistulas'. Together they form a unique fingerprint.

Cite this